Cite
HARVARD Citation
Dimopoulos, M. et al. (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet. 9 (6), pp. e403-e414. [Online].